A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Clinical trial NCT02637856 · COMPLETED
Trial details
- NCT number
- NCT02637856
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-11
- Primary completion
- 2019-05-03
- Enrollment
- 608
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.